AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
A legfontosabb adatok
- Ki végzi
- Amgen
- Hol
- Houston (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1. fázis
- Résztvevők
- 7 fő vett részt
- Kezdés
- 2022. nov. 14.
- Befejezés
- 2023. dec. 19.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoport
- A vizsgált kezelések
- AMG 176
- Azacitidine
- A regiszteradat frissítve
- 2025. július 14.
- Miért állt le
- Sponsor decision, unrelated to safety
Ki vehet részt
- Életkor
- 18 év – 85 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 8 feltétel megnézéseKevesebb
Ki vehet részt
- Age >= 18 years of age
- For Part 1, participants have R/R MDS post-HMA failure, defined as prior receipt of 4 cycles of HMA therapy (including but not limited to decitabine, azacitidine, investigational HMAs such as SGI-110, and oral HMAs such as oral decitabine and cedazuridine [ASTX727] and oral azacitidine [CC-486]) with failure to attain a response or progression of disease or relapse at any time after prior response to HMA therapy; Note: participants with HR-CMML (CMML-1 or 2 by World Health Organization [WHO]) are eligible. Hydroxyurea administration will be allowed on the study to lower the white cell count to <= 10 000/μL prior to the initiation of therapy
- For Part 2, participants will be divided into 2 cohorts:; HMA Failure Cohort: participants with R/R MDS post-HMA failure. Participants who have previously received venetoclax are eligible and will be stratified accordingly in the HMA failure cohort; Newly Diagnosed Cohort: Participants with treatment-naïve newly diagnosed HR-MDS (revised International Prognostic Scoring System [IPSS-R] score >3.5) are eligible for enrollment only after all prior cohorts have been completed. Hydroxyurea administration will be allowed on the study to lower the white cell count to <= 10 000/μL prior to the initiation of therapy. Participants with HR-CMML (CMML-1 or 2 by WHO) are eligible
Ki nem vehet részt
- Excluded prior and/or concomitant therapies as listed in the full list of criteria
- Participants who are fit and deemed eligible by the investigator for intensive salvage therapy
- History of other malignancy within the past 2 years prior to enrollment (with some exceptions as listed in full list of criteria)
- Participants with newly diagnosed MDS with Revised International Prognostic Scoring System (IPSS-R) lower-risk category (IPSS-R score < 3.5)
- Participants with CMML-0 by WHO
Helyszínek itt: Egyesült Államok
- University of Texas - MD Anderson Cancer CenterHouston, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The main objective is to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia (HR-MDS/CMML).
A vizsgálat 3 csoportja
- Part 1A - AMG 176 Monotherapy (Dose Exploration)A vizsgált kezelés
Two dose levels of AMG 176 will be tested in Part 1A to find the optimal biological dose/minimum safe biologically effective dose (OBD/MSBED).
Kezelés: AMG 176
- Part 1B - AMG 176 and Azacitidine Combination Therapy (Dose Exploration)A vizsgált kezelés
After the OBD is found in Part 1A, two dose levels of AMG 176 in combination with azacitidine will be tested in Part 1B to find the OBD/MSBED.
Kezelés: AMG 176 és Azacitidine
- Part 2 - AMG 176 and Azacitidine Combination Therapy (Dose Expansion)A vizsgált kezelés
After the completion of Part 1, the Part 2 dose expansion phase will begin at the OBD/MSBED identified in Part 1. Venetoclax-naïve and venetoclax-exposed R/R HR-MDS participants after HMA failure will be enrolled along with participants with newly diagnosed HR-MDS/CMML.
Kezelés: AMG 176 és Azacitidine
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1 Study of AMG 176 as Monotherapy and in Combination With Azacitidine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
- A regiszteradat frissítve
- 2025. július 14.